Careers  |  Sign In  |  Register
Course List
  • CME Information

Provider Statement:

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement:

This activity is supported by an independent educational grant from Merck & Co., Inc.

Target Audience:

The intended audience for the activity is gastroenterologists, infectious disease specialists, and other health care professionals involved in the treatment of patients with Clostridium difficile (C. difficile) infections.

Learning Objectives:

Upon successful completion of this activity, participants should be better able to:

  • Assess the increasing incidence of C. difficile infection, as well as hypervirulent strains, in and outside of the hospital setting.
  • Differentiate current treatment options for C. difficile infection in terms of safety, efficacy, and improvement of patient outcomes.


Clostridium difficile is a significant cause of infectious disease death in the United States, constituting a serious public health burden. According to the Centers for Disease Control and Prevention, nearly 250,000 people become infected with C. difficile during hospital stays each year, surpassing the number of methicillin-resistant Staphylococcus aureus infections. However, C. difficile infection (CDI) is not an exclusively nosocomial problem, and approximately one-third of infections are community associated. New therapies with greater efficacy and improved prevention of recurrence are required. In this expert interview, a leading clinician will discuss the increasing incidence and resistance of C. difficile, as well as hypervirulent strains, and evaluate current therapeutic agents for CDI in terms of safety, efficacy, and improvement of patient outcomes. 


Erik R. Dubberke, MD, MSPH
Associate Professor of Medicine
Director, Section of Transplant Infectious Diseases
Washington University School of Medicine
St. Louis, MO


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, September 5, 2017 to September 4, 2018.

How to Participate in this Activity and Obtain CME Credit:

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 posttest questions (75%) correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Peer Reviewer:

Craig Aronchick, MD


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

Faculty member reports the following relationship(s):

Erik R. Dubberke, MD, MSPH
Consulting Fee: Merck, Pfizer, Rebiotix, Sanofi Pasteur
Contracted Research: Merck, Pfizer, Rebiotix, Sanofi Pasteur

Peer Reviewer reports the following relationship(s):

Craig Aronchick, MD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Educational Tools:

Unlabeled and Investigational Usage:

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at